Arcus Biosciences is a clinical-stage biotechnology company with a promising pipeline but a business model heavily reliant on lumpy collaboration milestones, as evidenced by revenue swinging from $160M in 2025Q2 to $17M in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$1.00-12.3% vs -$0.89 | $9M+18.7% vs $8M |
Q3 2026 Aug 5, 2026 | -$0.72+19.2% vs -$0.89 | $41M+86.5% vs $22M |
Q2 2026 May 5, 2026 | -$1.02-10.9% vs -$0.92 | $17M-42.3% vs $29M |
Q1 2026 Feb 25, 2026 | -$0.89+19.8% vs -$1.11 | $33M-7.6% vs $36M |
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.27 per share a year ago.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “In October, we showed for the first time that robust and durable HIF-2.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced that its management team will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London, UK. The fireside chat will take place on Monday, November 16th, 2026, at 5:00pm GMT. A live webcast of the presentation will.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company's common stock at an exercise price per share of $18.54, which was the closing price.
Benchmark RCUS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arcus Biosciences, Inc. (RCUS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $69.57 | $17.49B | 20.10 | 6.98% | 35.45% | 45.54% | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — |
Arcus Biosciences, Inc. (RCUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arcus Biosciences, Inc. (RCUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 12, 2026·SEC
May 5, 2026·SEC
Get notified when RCUS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arcus Biosciences, Inc. (RCUS) stock FAQ — growth, dividends, profitability & financials explained
Arcus Biosciences, Inc. (RCUS) reported $100.0M in revenue over the trailing twelve months. Revenue was $247.0M in fiscal year 2025.
Arcus Biosciences, Inc. (RCUS) revenue fell by 58.3% over the trailing twelve months, compared with the twelve months before.
No. Arcus Biosciences, Inc. (RCUS) reported a net loss of $445.0M over the trailing twelve months.
Arcus Biosciences, Inc. (RCUS) had a return on equity (ROE) of -90.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Arcus Biosciences, Inc. (RCUS) had negative free cash flow of $466.0M over the trailing twelve months.
